ArticleACS infectious diseases2023
Synthesis and Testing of Analogs of the Tuberculosis Drug Candidate SQ109 against Bacteria and Protozoa: Identification of Lead Compounds against
Open access · greenAbstract read
In one paragraph
Article in ACS infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Ιdentification of SQ109 analogs with enhanced antimicrobial activity against methicillin-resistantAntimicrobial agents and chemotherapy · 2026Article
- Defining the Mechanism of Action and Resistance of NewACS chemical biology · 2026Article
- From Classics to Nano-Excipients and Biopolymers: Pulmonary Drug Delivery Formulations.Pharmaceutics · 2026Review
- Structural isomerisation affects the antitubercular activity of adamantyl-isoxyl adducts.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- The Tuberculosis Drug Candidate SQ109 and Its Analogs Have Multistage Activity againstACS infectious diseases · 2024Article
- Novel Inhibitors to MmpL3 Transporter ofACS omega · 2024Article
- Investigation into the Mechanism of Action of the Tuberculosis Drug Candidate SQ109 and Its Metabolites and Analogues in Mycobacteria.Journal of medicinal chemistry · 2023Article
- Study of SQ109 analogs binding to mycobacterium MmpL3 transporter using MD simulations and alchemical relative binding free energy calculations.Journal of computer-aided molecular design · 2023Article
- Interaction ofJournal of functional biomaterials · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 12 institutions in 7 countries.
Marianna StampolakiLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, Athens15771, Greece.
Satish R MalwalDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois61801, United States.ORCID 0000-0001-7606-1932
Nadine Alvarez-CabreraCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey07110, United States.
Zijun GaoDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois61801, United States.ORCID 0000-0002-2584-0079
Mohammad MoniruzzamanDepartment of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, 101 Stephenson Parkway, Norman, Oklahoma73019-5251, United States.
Svitlana O BabiiDepartment of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, 101 Stephenson Parkway, Norman, Oklahoma73019-5251, United States.
Nikolaos NazirisSection of Pharmaceutical Technology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, Athens15771, Greece.
André Rey-CibatiInstituto de Estudios Avanzados, Caracas, Venezuela Instituto de Biología Experimental, Facultad de Ciencias, Universidad Central de Venezuela (UCV), Caracas1050, Venezuela.
Mariana Valladares-DelgadoInstituto de Estudios Avanzados, Caracas, Venezuela Instituto de Biología Experimental, Facultad de Ciencias, Universidad Central de Venezuela (UCV), Caracas1050, Venezuela.
Andreea L TurcuLaboratori de Química Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, BarcelonaE-08028, Spain.
Kyung-Hwa BaekHost-Parasite Research Laboratory, Institut Pasteur Korea, Seongnam-si13488, Republic of Korea.
Trong-Nhat PhanHost-Parasite Research Laboratory, Institut Pasteur Korea, Seongnam-si13488, Republic of Korea.
Hyeryon LeeHost-Parasite Research Laboratory, Institut Pasteur Korea, Seongnam-si13488, Republic of Korea.
Mattheo AlcarazInstitut de Recherche en Infectiologie de Montpellier, CNRS UMR9004, Université de Montpellier, 1919 route de Mende, 34293Montpellier, France.
Savannah WatsonDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, Pretoria0028, South Africa.
Mariette van der WattDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, Pretoria0028, South Africa.
Dina CoertzenDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, Pretoria0028, South Africa.
Natasa EfstathiouLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, Athens15771, Greece.
Maria ChountoulesiSection of Pharmaceutical Technology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, Athens15771, Greece.
Carolyn M ShoenCentral New York Research Corporation, Veterans Affairs Medical Center, Syracuse, New York13210, United States.
Ioannis P PapanastasiouLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, Athens15771, Greece.ORCID 0000-0001-6974-2561
Jose BreaDrug Screening Platform/Biofarma Research Group, CIMUS Research Center, Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica, University of Santiago de Compostela (USC), 15782Santiago de Compostela, Spain.ORCID 0000-0002-5523-1979
Michael H CynamonCentral New York Research Corporation, Veterans Affairs Medical Center, Syracuse, New York13210, United States.
Lyn-Marié BirkholtzDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, Pretoria0028, South Africa.
Laurent KremerInstitut de Recherche en Infectiologie de Montpellier, CNRS UMR9004, Université de Montpellier, 1919 route de Mende, 34293Montpellier, France.ORCID 0000-0002-6604-4458
Joo Hwan NoHost-Parasite Research Laboratory, Institut Pasteur Korea, Seongnam-si13488, Republic of Korea.
Santiago VázquezLaboratori de Química Farmacèutica (Unitat Associada al CSIC), Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultat de Farmàcia i Ciències de l'Alimentació, and Institute of Biomedicine (IBUB), Universitat de Barcelona, Av. Joan XXIII, 27-31, BarcelonaE-08028, Spain.ORCID 0000-0002-9296-6026
Gustavo BenaimInstituto de Estudios Avanzados, Caracas, Venezuela Instituto de Biología Experimental, Facultad de Ciencias, Universidad Central de Venezuela (UCV), Caracas1050, Venezuela.
Costas DemetzosSection of Pharmaceutical Technology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, Athens15771, Greece.ORCID 0000-0001-9771-4314
Helen I ZgurskayaDepartment of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, 101 Stephenson Parkway, Norman, Oklahoma73019-5251, United States.ORCID 0000-0001-8929-4727
Thomas DickCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey07110, United States.
Eric OldfieldDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois61801, United States.ORCID 0000-0002-0996-7352
Antonios D KolocourisLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, Athens15771, Greece.ORCID 0000-0001-6110-1903
National and Kapodistrian University of Athens · GRInstitut Pasteur Korea · KRUniversity of Pretoria · ZAInstituto de Estudios Avanzados · VEUniversity of Illinois Urbana-Champaign · USUniversity of Oklahoma · USCentral New York Research Corporation · USCentre National de la Recherche Scientifique · FRUniversitat de Barcelona · ESGeorgetown University · USHackensack Meridian Health · USUniversidade de Santiago de Compostela · ES
Funding
Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung diseaseR01AI132374 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI Thomas Dick · 2018 to 2026
$7.0MMmpL3 as a target for novel anti-TB agentsR01AI116525 · NIAID · COLORADO STATE UNIVERSITY · PI JACKSON, MARY · 2015 to 2024
$5.3MNIAID NIH HHS R01 AI116525NIAID NIH HHS R01 AI132374
Abstract
SQ109 is a tuberculosis drug candidate that has high potency against
Indexed as
MalariaMycobacterium abscessusMycobacterium tuberculosisParasitesTuberculosisAnimalsAntitubercular AgentsBacterial ProteinsHumansLipidsAntitubercular AgentsBacterial ProteinsLipidsantibioticcalorimetryleishmaniasismalariasynthesistuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.